Please assess the completion status of the following clinical trial:

Trial Title: Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Relapsed or refractory acute myeloid leukemia (AML) after one first-line chemotherapy regimen~2. Patients aged 18 - 65 inclusively~3. European Cooperative Oncology Group (ECOG) performance status of less than 2~Exclusion Criteria:~1. Patients aged less than 18 or above 65~2. ECOG performance status of 2 or more~3. Acute promyelocytic leukaemia~4. Uncontrolled active infection~5. Uncontrolled arrhythmia~6. Altered renal dysfunction with serum creatinine \> 1.5 x ULN and/or creatinine clearance \< 50 mL/min~7. Significant neurologic (grade \> 2) or psychiatric disorder, dementia or seizures~8. Clinical symptoms suggesting active central nervous system leukemia~9. Severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock or disseminated intravascular coagulation~10. Patients with known HIV, Hepatitis B or C infection or history of cirrhosis~11. Patients Significant hepatic dysfunction: Direct bilirubin \> 1.5 x upper limit of normal (ULN) for age; ALT or AST \> 3 x upper limit of normal (ULN) for age; Lipase \> 2.0 x upper limit of normal (ULN) for age~12. Females of childbearing potential must have a negative pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Clofarabine, AraC, mitoxantrone (CLAM) (Type: OTHER): This is the single arm with the intervention using Clofarabine, AraC, Mitoxantrone

Based on this trial design, predict the completion outcome and termination type (if applicable).